LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Inicio・Lista de Acciones・Gilead Sciences Inc.

Gilead Sciences Inc.

Cerrado

SectorSanidad

129.48 0.26

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

128.92

Máximo

130.03

Métricas clave
By Trading Economics
Ingresos	-162M 2B
Ventas	-965M 7B
P/B Media del Sector	17.837 49.888
BPA	2.03
Rentabilidad por dividendo	2.37
Margen de beneficios	29.037
Empleados	17,000
EBITDA	1.2B 3.5B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+23.96% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	2.37% 2.38%
Próximas Ganancias	6 ago 2026
Fecha Próximo Dividendo	29 jun 2026
Próxima Fecha de Ex Dividendo	15 jun 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-1.9B 163B
Apertura anterior	129.22
Cierre anterior	129.48

Noticias sobre sentimiento de mercado

By Acuity

18%

82%

22 / 344 Clasificación en Healthcare

Gilead Sciences Inc. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 may 2026, 20:49 UTC

Ganancias

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

7 abr 2026, 14:24 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

7 abr 2026, 12:53 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

4 jun 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

8 may 2026, 08:10 UTC

Ganancias

Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost. -- Barrons.com

8 may 2026, 08:08 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 may 2026, 22:33 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 may 2026, 21:09 UTC

Ganancias

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 may 2026, 20:51 UTC

Ganancias

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 may 2026, 20:06 UTC

Ganancias

Gilead Sciences Raises 2026 View To Sales $30B-$30.4B >GILD

7 may 2026, 20:05 UTC

Ganancias

Gilead Sciences Sees 2026 Adj Loss/Shr 65c-Adj Loss/Shr $1.05 >GILD

7 may 2026, 20:05 UTC

Ganancias

Gilead Sciences Sees 2026 Loss/Shr $2.85-Loss $3.25 >GILD

7 may 2026, 20:02 UTC

Ganancias

Gilead Sciences: Biktarvy Sales Increased 7% Yr-Over-Yr to $3.4B >GILD

7 may 2026, 20:01 UTC

Ganancias

Gilead Sciences 1Q Rev $6.96B >GILD

7 may 2026, 20:01 UTC

Ganancias

Gilead Sciences 1Q Adj EPS $2.03 >GILD

7 may 2026, 20:01 UTC

Ganancias

Gilead Sciences 1Q Total Liver Disease Sales $767M >GILD

7 may 2026, 20:01 UTC

Ganancias

Gilead Sciences 1Q EPS $1.61 >GILD

28 abr 2026, 12:45 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

17 abr 2026, 12:32 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

17 abr 2026, 12:30 UTC

Adquisiciones, fusiones, absorciones

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

7 abr 2026, 14:36 UTC

Adquisiciones, fusiones, absorciones

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

7 abr 2026, 14:35 UTC

Adquisiciones, fusiones, absorciones

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

7 abr 2026, 14:34 UTC

Adquisiciones, fusiones, absorciones

EQT Life Sciences: Gilead Will Also Buy TUB-030

7 abr 2026, 14:28 UTC

Adquisiciones, fusiones, absorciones

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

7 abr 2026, 14:23 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Gilead Buying Another Cancer-Drug Partner -- Market Talk

7 abr 2026, 13:55 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

7 abr 2026, 13:14 UTC

Adquisiciones, fusiones, absorciones

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

7 abr 2026, 12:30 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

7 abr 2026, 12:30 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

7 abr 2026, 12:30 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

Comparación entre iguales

Cambio de precio

Gilead Sciences Inc. previsión

Precio Objetivo

By TipRanks

23.96% repunte

Estimación a 12 Meses

Media 160.11 USD 23.96%

Máximo 180 USD

Mínimo 122 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gilead Sciences Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

Comprar

Mantener

Vender

De acuerdo con 21 analistas que ofrecen calificaciones bursátiles a para Gilead Sciences Inc. Dist en los últimos 3 meses.

Sentimiento

By Acuity

22 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.